CBER (Center for Biologics Evaluation and Research) set to overhaul product review practices in response to industry demand
This article was originally published in Clinica
Executive Summary
The Center for Biologics Evaluation and Research is responding to industry complaints and plans to make its review processes more user-friendly. Karen Riley reports on how the US agency plans to gain popularity with a more streamlined scrutiny system.